mianserin has been researched along with Dyskinesia, Drug-Induced in 13 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia." | 9.08 | Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. ( Fujikawa, T; Furutani, M; Hayashi, T; Horiguchi, J; Nishikawa, T; Takahashi, T; Tawara, Y; Yamawaki, S; Yano, T; Yokota, N, 1997) |
| "The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia." | 5.08 | Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. ( Fujikawa, T; Furutani, M; Hayashi, T; Horiguchi, J; Nishikawa, T; Takahashi, T; Tawara, Y; Yamawaki, S; Yano, T; Yokota, N, 1997) |
| "Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor." | 2.74 | Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. ( Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N, 2009) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Rats treated with haloperidol at doses of 0." | 1.37 | Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats. ( Haleem, DJ; Shireen, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamadjida, A | 2 |
| Nuara, SG | 2 |
| Gourdon, JC | 2 |
| Huot, P | 2 |
| Veyres, N | 1 |
| Frouni, I | 1 |
| Kwan, C | 1 |
| Sid-Otmane, L | 1 |
| Harraka, MJ | 1 |
| Meco, G | 1 |
| Stirpe, P | 1 |
| Edito, F | 1 |
| Purcaro, C | 1 |
| Valente, M | 1 |
| Bernardi, S | 1 |
| Vanacore, N | 1 |
| Shireen, E | 1 |
| Haleem, DJ | 1 |
| Konitsiotis, S | 1 |
| Pappa, S | 1 |
| Mantas, C | 1 |
| Mavreas, V | 1 |
| Kohen, I | 1 |
| Sarcevic, A | 1 |
| Sparring Björkstén, K | 1 |
| Wålinder, J | 1 |
| Hayashi, T | 1 |
| Yokota, N | 1 |
| Takahashi, T | 1 |
| Tawara, Y | 1 |
| Nishikawa, T | 1 |
| Yano, T | 1 |
| Furutani, M | 1 |
| Fujikawa, T | 1 |
| Horiguchi, J | 1 |
| Yamawaki, S | 1 |
| Stevens, E | 1 |
| Roman, A | 1 |
| Houa, M | 1 |
| Razavi, D | 1 |
| Jaspar, N | 1 |
| Pact, V | 1 |
| Giduz, T | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Otani, K | 1 |
| Kaneko, S | 1 |
| Fukushima, Y | 1 |
| Kubota, S | 1 |
| Korsgaard, S | 1 |
| Gerlach, J | 1 |
| Christensson, E | 1 |
3 trials available for mianserin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychot | 2009 |
Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Double- | 1997 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
10 other studies available for mianserin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Second-Generation; Callithrix; Disease Models, Animal; Dose-Response | 2018 |
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyski | 2017 |
Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Ha | 2011 |
Acute reversible dyskinesia induced by mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Humans; Male | 2005 |
Mirtazapine in bupropion-induced dyskinesias: a case report.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Dyskinesia, D | 2006 |
Does mianserin induce involuntary movements in brain damaged patients?
Topics: Aged; Brain Damage, Chronic; Dyskinesia, Drug-Induced; Female; Humans; Mianserin; Movement Disorders | 1993 |
Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia.
Topics: Anti-Anxiety Agents; Anti-Dyskinesia Agents; Antidepressive Agents, Second-Generation; Antidepressiv | 1998 |
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; | 1999 |
Involuntary movements associated with mianserin treatment. A case report.
Topics: Adult; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Humans; Mianserin | 1989 |
Behavioral aspects of serotonin-dopamine interaction in the monkey.
Topics: Animals; Chlorocebus aethiops; Cyproheptadine; Dextroamphetamine; Dopamine; Dyskinesia, Drug-Induced | 1985 |